SHARE THIS ARTICLE
Cimzia
Cimzia Manufacturer – The Company Behind the Biologic Treatment
Feb 19, 2025
Autoimmune diseases are becoming increasingly common, affecting 7.6% to 9.4% of the global population. These conditions occur when the immune system mistakenly attacks the body’s own tissues, leading to chronic inflammation and long-term health complications that significantly impact patients’ quality of life.
To address this growing need, biologic medications have been developed to target specific immune system components. One such treatment is Cimzia (certolizumab pegol), a tumor necrosis factor (TNF) inhibitor approved for conditions like rheumatoid arthritis and Crohn’s disease.
In this article, we’ll explore the company behind Cimzia, examining its history, mission, and contributions to immunology, and how it has shaped the landscape of biologic treatments.
Key Takeaways
- UCB is a Belgium-based pharmaceutical company specializing in biologics and immunotherapies.
- Cimzia (certolizumab pegol) was FDA-approved in 2008 and is used to treat inflammatory diseases.
- UCB’s research focuses on rheumatology, gastroenterology, and neurology, with ongoing studies for new treatments.
- Patient support programs help improve accessibility and affordability for those prescribed Cimzia.
- Cimzia’s indications have expanded with continuous research into additional autoimmune conditions.
About: Trusted by over 2,000+ global clients since 2014, Maylips has become a leading supplier of cosmetic, skincare, and orthopedic products for medical and aesthetic professionals. Maylips offers a wide range of authentic brand-name products at competitive wholesale prices, sourced from around the world. If you’re looking to buy Cimzia online, contact our sales team for guidance.
About UCB and Its Focus on Immunology
UCB, a global biopharmaceutical company headquartered in Brussels, Belgium, specializes in immunology and biologics. It develops targeted therapies for autoimmune and chronic inflammatory diseases. With a presence in over 40 countries, UCB focuses on advancing treatments in rheumatology, gastroenterology, and neurology.
One of its key biologics, Cimzia (certolizumab pegol), is used to treat rheumatoid arthritis, psoriatic arthritis, and Crohn’s disease. UCB’s commitment to innovation and patient-centered care includes real-world studies, collaborations with healthcare providers, and personalized treatment strategies aimed at enhancing patient outcomes and quality of life.
Cimzia’s Development and Regulatory Approval
Cimzia first received FDA approval in 2008 for the treatment of moderate-to-severe Crohn’s disease. Over the years, its expanded indications have demonstrated its effectiveness across multiple inflammatory conditions, including:
- 2009: Approved for moderate-to-severe rheumatoid arthritis.
- 2013: Approved for active psoriatic arthritis and active ankylosing spondylitis.
- 2019: Approved for plaque psoriasis and non-radiographic axial spondyloarthritis.
These approvals underscore Cimzia’s versatility and efficacy in managing chronic inflammatory diseases. Its PEGylated formulation extends drug activity, allowing for flexible dosing schedules tailored to each patient’s needs, providing sustained symptom relief and improving quality of life.
For those wondering, “How long does Cimzia stay in your system?”, the drug has a half-life of approximately 14 days, meaning it can take several weeks to fully clear from the body.
Ongoing Research and Expansion of Cimzia’s Indications
Cimzia has an extensive clinical trial history, demonstrating its effectiveness across multiple inflammatory conditions. Initially FDA-approved for Crohn’s disease, it has since expanded to treat rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, plaque psoriasis, and non-radiographic axial spondyloarthritis.
Pivotal studies, including RAPID 1 and RAPID 2, have shown that Cimzia can quickly reduce symptoms and slow disease progression in rheumatoid arthritis patients. With over 80 clinical studies supporting its efficacy and safety, Cimzia has a well-established track record in immunology.
Ongoing research continues to explore new indications and optimized treatment protocols, further strengthening Cimzia’s role in managing chronic inflammatory diseases.
Patient Support and Accessibility Initiatives
UCB offers a range of patient assistance programs to improve access to Cimzia, helping eligible patients with financial support, insurance navigation, and co-pay reduction options. By prioritizing affordability, UCB ensures that more patients can receive the treatment they need without financial strain.
Cimzia is available in multiple countries, and UCB is actively working to expand its reach to underserved regions. The company is committed to improving global access to biologic treatments through partnerships with healthcare providers and government agencies.
Conclusion
UCB, the manufacturer of Cimzia, is a pioneer in biologic drug development, specializing in immunology and inflammatory disease treatments. With its proven effectiveness in Crohn’s disease, arthritis, and other chronic conditions, Cimzia continues to be a trusted treatment option for patients worldwide.
Ongoing research is further expanding Cimzia’s potential applications, reinforcing UCB’s commitment to innovation and advancing patient care. By prioritizing treatment accessibility, patient support, and continued scientific progress, UCB ensures that Cimzia remains a reliable and impactful solution for those managing chronic inflammatory diseases.
FAQs
1. What is Cimzia?
Cimzia (certolizumab pegol) is a biological medication used to treat autoimmune conditions such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and Crohn’s disease.
2. How long does it take for Cimzia to work?
Some patients notice improvements within a few weeks, while others may take several months. The response time varies depending on the condition being treated and individual factors.
3. What are the common side effects of Cimzia?
Common side effects include injection site reactions, headache, upper respiratory infections, nausea, and rash. Serious side effects, such as infections or allergic reactions, may occur but are less common.
4. Can I discontinue Cimzia anytime?
Stopping Cimzia without medical supervision may cause a flare-up of symptoms. If you need to discontinue treatment, consult your doctor for a proper plan to manage your condition.
References
Lerner A, Jeremias P, Matthias T. The World Incidence and Prevalence of Autoimmune Diseases is Increasing. International Journal of Celiac Disease. 2016;3(4):151-155. doi:10.12691/ijcd-3-4-8
Zhao M, Zhai H, Li H, et al. Age-standardized incidence, prevalence, and mortality rates of autoimmune diseases in adolescents and young adults (15–39 years): an analysis based on the global burden of disease study 2021. BMC Public Health. 2024;24(1). doi:https://doi.org/10.1186/s12889-024-19290-3
Cimzia | European Medicines Agency (EMA). European Medicines Agency (EMA). Published March 20, 2008. Accessed February 19, 2025. https://www.ema.europa.eu/en/medicines/human/EPAR/cimzia-0
Highlights of Prescribing Information for Cimzia. FDA. Accessed February 19, 2025. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/125160s275lbl.pdf